Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the most common targeted drugs and play a crucial role in treating non-small cell lung cancer with EGFR gene mutations (10, 13–15). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.